



## GENMAB TO ATTEND THREE JUNE INVESTOR CONFERENCES

*Summary: Genmab's management will attend three investor conferences during the month of June.*

**Copenhagen, Denmark; June 4, 2008** – Genmab A/S (OMX: GEN) announced today its management will attend three investor conferences in June 2008. Lisa Drakeman Ph.D., Chief Executive Officer of Genmab will present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on June 11, 2008 at 10:40AM local time at The Ritz-Carlton Laguna Niguel in Dana Point, California, and at the Jefferies 2nd Annual Healthcare Conference on June 25, 2008 at 1:30PM EDT in New York City, New York. Professor Jan van de Winkel, President, Research & Development & Chief Scientific Officer will present at the Piper Jaffray Europe Conference at the ANdAZ Hotel (formerly Great Eastern Hotel) in London on June 24, 2008 at 11.20AM local time. Live and archived webcasts of the presentations will be available at [www.genmab.com](http://www.genmab.com).

### **About Genmab A/S**

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit [www.genmab.com](http://www.genmab.com).

*This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.*

Genmab<sup>®</sup>; the Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; HuMax-CD4<sup>®</sup>; HuMax-CD20<sup>®</sup>; HuMax-EGFr<sup>™</sup>; HuMax-IL8<sup>™</sup>; HuMax-TAC<sup>™</sup>; HuMax-HepC<sup>™</sup>; HuMax-CD38<sup>™</sup>; HuMax-CD32b<sup>™</sup> and UniBody<sup>®</sup> are all trademarks of Genmab A/S.

## GENMAB TO ATTEND THREE JUNE INVESTOR CONFERENCES

Contact: Helle Husted, Sr. Director, Investor Relations  
T: +45 33 44 77 30; M: +45 25 27 47 13; E: [hth@genmab.com](mailto:hth@genmab.com)  
###

